Literature DB >> 22939943

Osteocyte control of osteoclastogenesis.

Charles A O'Brien1, Tomoki Nakashima, Hiroshi Takayanagi.   

Abstract

Multiple lines of evidence support the idea that osteocytes act as mechanosensors in bone and that they control bone formation, in part, by expressing the Wnt antagonist sclerostin. However, the role of osteocytes in the control of bone resorption has been less clear. Recent studies have demonstrated that osteocytes are the major source of the cytokine RANKL involved in osteoclast formation in cancellous bone. The goal of this review is to discuss these and other studies that reveal mechanisms whereby osteocytes control osteoclast formation and thus bone resorption. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22939943      PMCID: PMC3538915          DOI: 10.1016/j.bone.2012.08.121

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  87 in total

Review 1.  Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.

Authors:  S C Manolagas
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

Review 2.  Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression.

Authors:  A M Parfitt
Journal:  Bone       Date:  2002-01       Impact factor: 4.398

3.  The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated.

Authors:  F Gori; L C Hofbauer; C R Dunstan; T C Spelsberg; S Khosla; B L Riggs
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

4.  In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene.

Authors:  J E Onyia; R R Miles; X Yang; D L Halladay; J Hale; A Glasebrook; D McClure; G Seno; L Churgay; S Chandrasekhar; T J Martin
Journal:  J Bone Miner Res       Date:  2000-05       Impact factor: 6.741

5.  Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency.

Authors:  M Kanematsu; T Sato; H Takai; K Watanabe; K Ikeda; Y Yamada
Journal:  J Bone Miner Res       Date:  2000-07       Impact factor: 6.741

6.  Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).

Authors:  W Balemans; M Ebeling; N Patel; E Van Hul; P Olson; M Dioszegi; C Lacza; W Wuyts; J Van Den Ende; P Willems; A F Paes-Alves; S Hill; M Bueno; F J Ramos; P Tacconi; F G Dikkers; C Stratakis; K Lindpaintner; B Vickery; D Foernzler; W Van Hul
Journal:  Hum Mol Genet       Date:  2001-03-01       Impact factor: 6.150

7.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

Authors:  M E Brunkow; J C Gardner; J Van Ness; B W Paeper; B R Kovacevich; S Proll; J E Skonier; L Zhao; P J Sabo; Y Fu; R S Alisch; L Gillett; T Colbert; P Tacconi; D Galas; H Hamersma; P Beighton; J Mulligan
Journal:  Am J Hum Genet       Date:  2001-02-09       Impact factor: 11.025

8.  Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease.

Authors:  W Balemans; N Patel; M Ebeling; E Van Hul; W Wuyts; C Lacza; M Dioszegi; F G Dikkers; P Hildering; P J Willems; J B G M Verheij; K Lindpaintner; B Vickery; D Foernzler; W Van Hul
Journal:  J Med Genet       Date:  2002-02       Impact factor: 6.318

9.  A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population.

Authors:  Karen Staehling-Hampton; Sean Proll; Bryan W Paeper; Lei Zhao; Patrick Charmley; Analisa Brown; Jessica C Gardner; David Galas; Randall C Schatzman; Peter Beighton; Socrates Papapoulos; Herman Hamersma; Mary E Brunkow
Journal:  Am J Med Genet       Date:  2002-06-15

10.  Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.

Authors:  Hisatomo Kondo; Jun Guo; F Richard Bringhurst
Journal:  J Bone Miner Res       Date:  2002-09       Impact factor: 6.741

View more
  87 in total

1.  Deficiency of circadian clock protein BMAL1 in mice results in a low bone mass phenotype.

Authors:  William E Samsa; Amit Vasanji; Ronald J Midura; Roman V Kondratov
Journal:  Bone       Date:  2016-01-14       Impact factor: 4.398

2.  Nox2 Activity Is Required in Obesity-Mediated Alteration of Bone Remodeling.

Authors:  Md Mizanur Rahman; Amina El Jamali; Ganesh V Halade; Allal Ouhtit; Haissam Abou-Saleh; Gianfranco Pintus
Journal:  Oxid Med Cell Longev       Date:  2018-11-08       Impact factor: 6.543

3.  MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production.

Authors:  Jesus Delgado-Calle; Benjamin Hancock; Elive F Likine; Amy Y Sato; Kevin McAndrews; Carolina Sanudo; Angela Bruzzaniti; Jose A Riancho; James R Tonra; Teresita Bellido
Journal:  FASEB J       Date:  2018-01-17       Impact factor: 5.191

4.  Age-related marrow adipogenesis is linked to increased expression of RANKL.

Authors:  Sunao Takeshita; Toshio Fumoto; Yoshinori Naoe; Kyoji Ikeda
Journal:  J Biol Chem       Date:  2014-04-21       Impact factor: 5.157

5.  Osteocyte culture in microfluidic devices.

Authors:  Chao Wei; Beiyuan Fan; Deyong Chen; Chao Liu; Yuanchen Wei; Bo Huo; Lidan You; Junbo Wang; Jian Chen
Journal:  Biomicrofluidics       Date:  2015-01-26       Impact factor: 2.800

Review 6.  Podosome organization drives osteoclast-mediated bone resorption.

Authors:  Dan Georgess; Irma Machuca-Gayet; Anne Blangy; Pierre Jurdic
Journal:  Cell Adh Migr       Date:  2014       Impact factor: 3.405

7.  Communication of cAMP by connexin43 gap junctions regulates osteoblast signaling and gene expression.

Authors:  Aditi Gupta; Hidayah Anderson; Atum M Buo; Megan C Moorer; Margaret Ren; Joseph P Stains
Journal:  Cell Signal       Date:  2016-05-06       Impact factor: 4.315

Review 8.  Integration of denosumab therapy in the management of giant cell tumors of bone.

Authors:  Daniel T Miles; Ryan T Voskuil; Wood Dale; Joel L Mayerson; Thomas J Scharschmidt
Journal:  J Orthop       Date:  2020-03-28

Review 9.  Parathyroid hormone: anabolic and catabolic actions on the skeleton.

Authors:  Barbara C Silva; John P Bilezikian
Journal:  Curr Opin Pharmacol       Date:  2015-04-05       Impact factor: 5.547

Review 10.  Shifting paradigms on the role of connexin43 in the skeletal response to mechanical load.

Authors:  Shane A Lloyd; Alayna E Loiselle; Yue Zhang; Henry J Donahue
Journal:  J Bone Miner Res       Date:  2014-02       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.